



European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology

Suleman Aktaa ^{1,2,3*}, Baris Gencer^{4,5}, Elena Arbelo ^{6,7,8},
Constantinos H. Davos ⁹, Ileana Désormais¹⁰, Monika Hollander¹¹, Ana Abreu¹²,
Marco Ambrosetti¹³, Maria Bäck^{14,15}, David Carballo¹⁶, Carolyn Crawford¹⁷,
Christi Deaton ¹⁸, Paul Dendale ¹⁹, Thijs M.H. Eijvogels²⁰, Mary Galbraith¹⁷,
Massimo Francesco Piepoli²¹, Annett Salzwedel²², Yvo Smulders²³,
Matthias Wilhelm²⁴, Giuseppe Biondi-Zoccai ^{25,26}, François Mach ⁴,
Frank L.J. Visseren²⁷, and Chris P. Gale^{1,2,3}

¹Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9LU, UK; ²Leeds Institute for Data Analytics, University of Leeds, Leeds LS2 9LU, UK; ³Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; ⁴Division of Cardiology, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland; ⁵Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland; ⁶Arrhythmia Section, Cardiology Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; ⁷IDIBAPS, Institut d'Investigació August Pi i Sunyer (IDIBAPS), Barcelona, Spain; ⁸Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; ⁹Cardiovascular Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece; ¹⁰Department of Thoracic and Cardiovascular Surgery and Angiology, Dupuytren University Hospital, Limoges, France; ¹¹Department of General Practice, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Universiteitsweg 100, Utrecht 3584 CG, The Netherlands; ¹²Cardiology Department, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte, (CHULN) Lisboa, Lisbon, Portugal; ¹³Cardiovascular Rehabilitation Unit, ASST Crema, Rivolta D'Adda Hospital, Rivolta D'Adda, Italy; ¹⁴Unit of Physiotherapy, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden; ¹⁵Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, and Sahlgrenska University Hospital, Gothenburg, Sweden; ¹⁶Department of Cardiology, Cardiovascular Center, University Hospital Geneva, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, Switzerland; ¹⁷ESC Patient Forum, Sophia Antipolis, France; ¹⁸Department of Public Health and Primary Care, University of Cambridge School of Clinical Medicine, Forvie Site, Cambridge Biomedical Campus, Cambridge CB22 5DT, UK; ¹⁹Heart Centre Hasselt and Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium; ²⁰Department of Physiology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; ²¹Heart Failure Unit, Cardiology, Guglielmo da Saliceto Hospital, and University of Parma, Piacenza, Italy; ²²Department of Rehabilitation Medicine, Faculty of Health Sciences Brandenburg, University of Potsdam, Potsdam, Germany; ²³Department of Internal Medicine and Geriatrics, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands; ²⁴Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; ²⁵Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; ²⁶Mediterranea Cardiocentro, Napoli, Italy; and ²⁷Department of Vascular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, Utrecht, The Netherlands

Received 1 August 2021; accepted 7 September 2021; online publish-ahead-of-print 23 October 2021

Aims

To develop a set of quality indicators (QIs) for the evaluation of the care and outcomes for atherosclerotic cardiovascular disease (ASCVD) prevention.

Methods and results

The Quality Indicator Committee of the European Society of Cardiology (ESC) formed the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with Task Force members of the 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice and the European Association of Preventive Cardiology (EAPC). We followed the ESC methodology for QI development, which involved (i) the identification of the key domains of care for ASCVD prevention by constructing a conceptual framework of care, (ii) the development of candidate QIs by conducting a systematic review of the literature, (iii) the selection of the final set of QIs using a modified Delphi method, and (iv) the evaluation of the feasibility of the developed QIs. In total, 17 main and 14 secondary QIs were selected across six domains of care for ASCVD prevention: (i) structural framework, (ii) risk assessment, (iii) care for people at risk for ASCVD, (iv) care for patients with established ASCVD, (v) patient education and experience, and (vi) outcomes.

Conclusion

We present the 2021 ESC QIs for Cardiovascular Disease Prevention, which have been co-constructed with EAPC using the ESC methodology for QI development. These indicators are supported by evidence from the literature, underpinned by expert consensus and aligned with the 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice to offer a mechanism for the evaluation of ASCVD prevention care and outcomes.

Keywords Cardiovascular disease • Atherosclerosis • Preventive cardiology • Quality indicators • Clinical practice guidelines

Introduction

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of mortality globally.¹ Evidence suggests that large proportions of individuals at high cardiovascular disease risk have unhealthy lifestyles and inadequate control of blood pressure, lipids, and diabetes.^{2,3} Although the advent of effective treatments for ASCVD has led to a reduction in morbidity and mortality,⁴ future challenges involve improving adherence to guideline-recommended therapies, optimizing patients' risk factors and modifying lifestyle behaviours to prevent the development and progression of ASCVD.⁵ To that end, international registries such as the European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) have demonstrated gaps in care delivery and geographic variation in clinical practice.⁶

Quality indicators (QIs) are tools that may provide a means to evaluate the implementation of guideline-recommended therapies.⁷ The US federal Agency for Healthcare Research and Quality (AHRQ) has developed prevention QIs for a range of clinical conditions, some of which are relevant to ASCVD.⁸ These indicators have been used to describe temporal and spatial patterns of the outcomes of preventive care.^{9,10} However, they do not include structural and process components of care, which are known to be more relevant to the delivery of care.¹¹ Professional Societies including the European Association of Preventive Cardiology (EAPC) have also developed quality measures for aspects of ASCVD.^{12–20} Each focus on particular elements of ASCVD prevention (primary prevention,¹⁶ hypertension,¹⁵ dyslipidaemia,¹⁷ and cardiac rehabilitation^{12,14,18,20}) or are directed to a particular clinical setting, such as primary care.^{13,19} However, there is no single contemporary set of QIs that encapsulates the wider aspect of cardiovascular disease prevention to allow a holistic evaluation of care.

Therefore, in parallel with the development of the 2021 European Society of Cardiology (ESC) Guidelines on Cardiovascular Disease Prevention in Clinical Practice, the ESC Quality Indicator Committee formed the Working Group for Cardiovascular Disease Prevention QIs in collaboration with EAPC to develop a comprehensive set of QIs for the prevention of ASCVD. This document presents the 2021 ESC QIs for ASCVD prevention in line with other ESC Clinical

Practice Guidelines.^{21,22} The ESC and EAPC anticipate that such QIs may facilitate the standardized evaluation of ASCVD prevention care and outcomes, and therefore identify where improvement initiatives may be used to reduce the burden of cardiovascular disease.

Methods

We followed the ESC methodology for the development of QIs for the quantification of cardiovascular care and outcomes.⁷ In brief, this involves (i) the identification of the key domains of ASCVD preventive care by constructing a conceptual framework of care delivery, (ii) the development of candidate QIs by conducting a systematic review of the literature, (iii) the selection of the final set of QIs using a modified Delphi method, and (iv) the evaluation of the feasibility of the developed QIs.⁷ The ESC QIs include main and secondary indicators. The main indicators were deemed to have higher validity and feasibility by the Working Group members and thus may be used for performance measurement across regions and over time. Both the main and secondary QIs may be used for local quality improvement activities.⁷

Members of the Working Group

The Working Group comprised Task Force members of the 2021 Guidelines on Cardiovascular Disease Prevention in Clinical Practice, EAPC representatives, patients, and international experts in ASCVD prevention, as well as members of the ESC Quality Indicator Committee. A series of virtual meetings were convened between the members of the Working Group from December 2020 until June 2021.

Target population and domains of care

The initial phase of the development process involved the identification of the 'target population' and the key domains of ASCVD preventive care. The 'target population' for whom the QIs are intended was defined as patients with established or high risk for ASCVD, and the key domains of care were selected accordingly by constructing a conceptual illustration of the multi-layered care pathway for this group of patients.⁷ To facilitate the operationalization of the

developed QIs, ASCVD was defined as 'atherosclerotic clinical conditions, including acute/chronic coronary syndrome, coronary artery disease documented by computed tomography (CT)/invasive coronary angiography, coronary or other arterial revascularization, stroke, transient ischaemic attack, documented carotid, aortic, peripheral artery disease, or atherosclerotic renovascular disease'. Patients at high risk for ASCVD were defined as those with no documented ASCVD diagnosis, but with diabetes mellitus, hypertension, moderate-severe renal disease, smoking history, familial hyperlipidaemia or other lipid disorder and who were deemed at high or very high risk for ASCVD according to the 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice.⁵

Specifications were defined for each of the QIs. These included a numerator, which is the group of patients for whom the QI was delivered, and, with the exception of the structural QIs, a denominator, which is the group of patients eligible for the QI. We also defined a measurement period (the time point at which the assessment is performed) and a measurement duration (the time frame needed for enough cases to be collected).⁷ Structural QIs are designed as binary measurements evaluating the availability of services in healthcare centres or units involved in the management of patients with established or high risk for ASCVD.

Systematic review

Search strategy

We conducted a systematic review of the published literature in accordance with the Preferred Reporting Items for Systematic Review and Meta-analyses statement (Supplementary material online, Appendix Table A1).²³ We searched two online bibliographic databases; MEDLINE and Embase via OVID (Wolters Kluwer, Alphen aan den Rijn, Netherlands). The initial search strategy was developed in MEDLINE using keywords and medical subject headings (MeSH) terms, such as 'primary prevention', 'secondary prevention', 'cardiac rehabilitation', 'health education', 'smoking cessation', and 'exercise' (for full list see Supplementary material online, Appendix Table A2). Further potential articles were identified using citation-searching and hand-searching of the references of identified articles.

We only included the primary publication of randomized controlled trials, and included the main publications of major trials from which our search obtained only sub-studies. We excluded systematic reviews, meta-analyses, editorials, letters, and conference proceedings. The search was restricted to English language reports and publication dates between 01 January 2016 and 08 March 2021. The search was restricted to the period after 2016 because this year corresponds to the publication of the previous ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice, thus ensuring current validity and applicability.²⁴

Eligibility criteria

We included articles fulfilling the following criteria: (i) the study population was adult patients (≥ 18 years old) with established or with risk factors for ASCVD, (ii) the study defined an intervention (structural or process aspect of preventive care) for which at least one outcome measure was reported, (iii) the outcome measures were hard endpoints (e.g. mortality, re-admission) or patient-reported outcomes (e.g. quality of life), (iv) the study provided definitions for the

intervention and outcome measure(s) evaluated, and (v) the study was a peer-reviewed randomized controlled trial. No restriction was placed on sample sizes, but studies which reported surrogate outcomes (e.g. biomarkers) as the main endpoints were excluded.

Study selection

EndNote X9 (Clarivate Analytics, London, UK) was used for reference management and for duplicates removal. Each retrieved study was independently evaluated by two reviewers (S.A. and C.D., B.G. and I.D., or E.A. and M.H.) against prespecified inclusion criteria. Disagreements were resolved through discussions and full-text review of the article.

Quality assessment and data extraction

Studies that met the eligibility criteria were included in the initial phase of the review. The broad inclusion was important to ensure that a list of initial (candidate) QIs was representative of a wide range of preventive care. For each included study, both the intervention studied and the outcome measure(s) that were evaluated were extracted. The variables were then classified according to their domain of care and to the type of the measurement (structural, process, or outcome).⁷ Definitions of the data items extracted were also obtained when provided in the studies.

Clinical practice guidelines and existing QIs

In addition to the systematic review, Clinical Practice Guidelines pertinent to the prevention of ASCVD were reviewed.²⁴⁻³⁰ The goal of the Clinical Practice Guidelines review was to assess the suitability of their recommendations with the strongest association with benefit and harm (Class I and III, respectively) against the ESC criteria for QIs (Supplementary material online, Appendix Table A3).⁷ Existing QIs and 'performance measures' relevant to ASCVD prevention¹¹⁻²⁰ were considered as candidate QIs using the same criteria.

Data synthesis

Modified Delphi process

The modified Delphi approach was used to evaluate the candidate QIs derived from the literature review.⁷ The Working Group members were made aware of the ESC criteria for QI development (Supplementary material online, Appendix Table A3) to standardize the voting process, and each candidate QI was ranked by each panellist on a 9-point ordinal scale for both validity and feasibility using an online questionnaire.⁷ In total, two rounds of voting were conducted, with a number of teleconferences after each round to discuss the results of the vote and to address any concerns, questions, or ambiguities.

Analysing voting results

The 9-point ordinal scale used for voting implied that ratings of 1-3 meant that the QI is not valid/feasible; ratings of 4-6 meant that the QI is of an uncertain validity/feasible; and ratings of 7-9 meant that the QI is valid/feasible. For each candidate QI, the median and the mean deviation from the median were calculated to evaluate the central tendency and the dispersion of the votes. Indicators, with median scores ≥ 7 for validity, ≥ 4 for feasibility, and with minimal dispersion, were included in the final set of QIs.⁷ The candidate QIs that met the numerical threshold for inclusion in the first voting round were

defined as main QIs, whilst those that met the inclusion criteria after the second round of voting were defined as secondary indicators.

Results

Domains of ASCVD prevention

The Working Group identified six domains of preventive care for ASCVD during the early phases of the development process. These domains capture the spectrum of ASCVD prevention care and outcomes irrespective of the healthcare institution at which the performance measurement is taking place, and in line with the EAPC Core Curriculum for Preventive Cardiology.³¹ The domains are:

- (i) structural framework, (ii) risk assessment, (iii) care for people at risk for ASCVD, (iv) care for patients with established ASCVD, (v) patient education and experience, and (vi) outcomes.

Systematic review results

The literature search retrieved 1026 articles, of which 158 met the inclusion criteria (Figure 1). In total, 75 potential QIs were extracted from the included studies. Of those, 51 candidate QIs were included in the first Delphi round. The remaining 24 indicators overlapped with other ESC QIs, such as those for acute myocardial infarction,³² atrial fibrillation,³³ heart failure, or cardiac pacing,³⁴ and were, thus, removed.




Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart of the systematic review.




Figure 2 2021 ESC EAPC Quality Indicators for ASCVD Prevention. ACR, albumin creatinine ratio; APT, antiplatelet therapy; ASCVD, atherosclerosis cardiovascular disease; Ax, assessment; BP, blood pressure; CAC, coronary calcium scoring; CE, cardioembolic; CKD, chronic kidney disease; CR, cardiac rehabilitation; CV, cardiovascular; CVH, cardiovascular hospitalization; DM, diabetes mellitus; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonists; HbA1c, glycated haemoglobin; HBR, high bleeding risk; HTN, hypertension; LDL-C, low-density lipoprotein cholesterol; MDT, multidisciplinary team; MI, myocardial infarction; PAD, peripheral artery disease; PPI, proton pump inhibitors; PREMs, patient-reported experience measures; RAASi, renin-angiotensin-aldosterone system inhibitors; Rx, treatment; SGLT2i, sodium/glucose cotransporter-2 inhibitors; TTE, transthoracic echocardiogram.

Modified Delphi results

Following the first round of voting, 23/51 (45%) candidate QIs were excluded; 17/51 (33%) met the inclusion threshold and thus were included as main QIs. The remaining 11/51 (22%) were deemed inconclusive and were carried to the second voting round. The excluded QIs ($N = 23$) were reviewed by the Working Group in subsequent meetings and agreement reached to reconsider modified versions of 16/23 (70%) in the second round of voting. As such, a total of 27 QIs (11 inconclusive and 16 modified) were included in the second

Delphi round, following which 14/27 (52%) were included as secondary QIs. [Figure 2](#) shows the main and the secondary indicators of the 2021 ESC EAPC Quality Indicators for ASCVD Prevention across six domains of care.

Quality indicators

Domain 1: Structural framework

This domain evaluates the characteristics of the centres that provide preventive care for patients with established or high risk for ASCVD. While the association between structural QIs and favourable patient

Table 1 2021 European Society of Cardiology quality indicators for cardiovascular disease prevention**Domain 1. Structural framework**

Main 1.1 Healthcare centres should have access to a multidisciplinary team dedicated to CVD prevention who deliver lifestyle modification (including diet, exercise, and alcohol consumption) advice and medication adherence counselling for patients with risk factors for or established ASCVD.

Numerator: Healthcare centres or units involved in the management of patients with established or high risk for ASCVD that have a dedicated multidisciplinary team.

Main 1.2 Healthcare centres should have access to a smoking cessation programme for patients with risk factors for or established ASCVD.

Numerator: Healthcare centres or units involved in the management of patients with established or high risk for ASCVD that have access to a smoking cessation programme.

Main 1.3 Healthcare centres should have access to 12-lead ECG, ambulatory ECG Holter monitoring, transthoracic echocardiogram, and CT calcium scoring to facilitate the assessment of patients with established or high risk for ASCVD.

Numerator: Healthcare centres or units involved in the management of patients with established or high risk for ASCVD that have access to 12-lead ECG, ambulatory ECG Holter monitoring, transthoracic echocardiogram, and CT calcium scoring.

Secondary 1.1 Healthcare centres should participate in a registry or common database to record clinical data relevant to cardiovascular risk (BMI, BP, LDL-C, HbA1c, and renal function) for patients with established or high risk for ASCVD.

Numerator: Healthcare centres or units involved in the management of patients with established or high risk for ASCVD that participate in a registry or common database to record patients' BMI, BP, LDL-C, HbA1c, and renal function.

Secondary 1.2 Healthcare centres should have available written protocols that encourage and facilitate disease self-measurement for patients with hypertension and/or diabetes.

Numerator: Healthcare centres or units involved in the management of patients with established or high risk for ASCVD that have available written protocols to encourage and facilitate disease self-measurement for patients with hypertension and/or diabetes.

Domain 2. Risk assessment

Main 2.1 Proportion of patients with established ASCVD who have their kidney function (eGFR and albuminuria) checked at least once and if had new treatment or event.

Numerator: Patients with established ASCVD who have their eGFR and albuminuria checked at least once and if had new treatment or event.

Denominator: Patients with established ASCVD.

Main 2.2 Proportion of patients with established ASCVD who have their lipid profile checked at least once and if had new treatment or event.

Numerator: Patients with established ASCVD who have their lipid profile checked at least once and if had new treatment or event.

Denominator: Patients with established ASCVD.

Main 2.3 Proportion of patients with established ASCVD who are screened for diabetes (with fasting blood glucose and/or HbA1c) at least annually.

Numerator: Patients with established ASCVD who are not known to have diabetes and have their fasting blood glucose and/or HbA1c checked at least annually.

Denominator: Patients with established ASCVD who are not known to have diabetes.

Main 2.4 Proportion of patients with established ASCVD who are screened for hypertension at least annually.

Numerator: Patients with established ASCVD who are not known to have hypertension and have their BP measured^a at least annually.

Denominator: Patients with established ASCVD who are not known to have hypertension.

Main 2.5 Proportion of patients with diabetes who have their HbA1c checked at least annually.

Numerator: Patients with diabetes who have their HbA1c checked at least annually.

Denominator: Patients with diabetes.

Secondary 2.1 Proportion of patients with established or high risk for ASCVD who have follow up at least annually to assess and address cardiovascular risk factors.

Numerator: Patients with established or high risk for ASCVD who have follow-up at least annually to assess and address cardiovascular risk factors.

Denominator: Patients with established or high risk for ASCVD.

Domain 3. Care for people at risk for ASCVD

Main 3.1 Proportion of patients 40–70 years of age with very high risk for ASCVD and a baseline LDL-C ≥ 1.8 mmol/L (≥ 70 mg/dL) who are prescribed lipid lowering therapy.

Numerator: Patients between 40 and 70 years of age with very high risk for ASCVD and a baseline LDL-C ≥ 1.8 mmol/L (≥ 70 mg/dL) who are prescribed lipid lowering therapy.

Denominator: Patients between 40 and 70 years of age with very high risk for ASCVD and a baseline LDL-C ≥ 1.8 mmol/L (≥ 70 mg/dL) who have no contraindication, refusal, or history of intolerance to lipid lowering therapy.

Main 3.2 Proportion of patients with diabetes and chronic kidney disease or hypertension who are prescribed renin–angiotensin–aldosterone system inhibitors.

Continued

Table 1 Continued

<p>Numerator: Patients with diabetes and chronic kidney disease or hypertension who are prescribed renin–angiotensin–aldosterone system inhibitors.</p> <p>Denominator: Patients with diabetes and chronic kidney disease or hypertension who have no contraindication, refusal, or history of intolerance to renin–angiotensin–aldosterone system inhibitors.</p> <p>Secondary 3.1 Proportion of patients with type 2 diabetes and chronic kidney disease who are prescribed SGLT2 inhibitors.</p> <p>Numerator: Patients with type 2 diabetes and chronic kidney disease who are prescribed SGLT2 inhibitors.</p> <p>Denominator: Patients with type 2 diabetes and chronic kidney disease who have no contraindication, refusal, or history of intolerance to SGLT2 inhibitors.</p>
<p>Domain 4. Care for patients with established ASCVD</p> <p>Main 4.1 Proportion of patients with established ASCVD and type 2 diabetes who are prescribed SGLT2 inhibitor or GLP-1RA.</p> <p>Numerator: Patients with established ASCVD and type 2 diabetes who are prescribed SGLT2 inhibitor or GLP-1RA.</p> <p>Denominator: Patients with established ASCVD and type 2 diabetes who have no contraindication, refusal, or history of intolerance to SGLT2 inhibitor and GLP-1RA.</p> <p>Main 4.2 Proportion of patients with symptomatic peripheral artery disease who are prescribed appropriate antiplatelet therapy.</p> <p>Numerator: Patients with symptomatic peripheral artery disease who are prescribed appropriate antiplatelet therapy.^b</p> <p>Denominator: Patients with symptomatic peripheral artery disease who have no contraindication, refusal, or history of intolerance to antiplatelet therapy, no indication for anticoagulation, and have not undergone a revascularization procedure within 1 month.</p> <p>Main 4.3 Proportion of patients with established ASCVD and BP $\geq 140/90$ mmHg who are prescribed BP lowering treatment.</p> <p>Numerator: Patients with established ASCVD and documented BP $\geq 140/90$ mmHg who are prescribed BP lowering treatment.^c</p> <p>Denominator: Patients with established ASCVD and documented BP $\geq 140/90$ mmHg who have no contraindication, refusal, or history of intolerance to BP lowering treatment.^c</p> <p>Main 4.4 Proportion of patients with established ASCVD who participate in a cardiac rehabilitation programme following an acute cardiovascular event or an elective revascularization procedure.</p> <p>Numerator: Patients with established ASCVD who are referred to cardiac rehabilitation programme at the time of hospital discharge following an acute cardiovascular event or an elective revascularization procedure.</p> <p>Denominator: Patients with established ASCVD following an acute cardiovascular event or an elective revascularization procedure who have not refused referral to cardiac rehabilitation programme.</p> <p>Secondary 4.1 Proportion of patients with a non-cardioembolic ischaemic (or embolic of undetermined source) stroke or TIA who are prescribed appropriate antiplatelet therapy.</p> <p>Numerator: Patients with non-cardioembolic ischaemic (or embolic of undetermined source) stroke or TIA who are prescribed appropriate antiplatelet therapy.^d</p> <p>Denominator: Patients with non-cardioembolic ischaemic (or embolic of undetermined source) stroke or TIA who have no contraindication, refusal, or history of intolerance to antiplatelet therapy, have no indication for anticoagulation, and have not undergone a revascularization procedure within 1 month.</p> <p>Secondary 4.2 Proportion of patients on antiplatelets therapy for ASCVD who have high bleeding risk and are prescribed a proton-pump inhibitor.</p> <p>Numerator: Patients on antiplatelets therapy for ASCVD and have high bleeding risk^e who are prescribed a proton-pump inhibitor.</p> <p>Denominator: Patients who are on antiplatelets therapy for ASCVD and have high bleeding risk^e with no contraindication, refusal, or history of intolerance to proton-pump inhibitor.</p>
<p>Domain 5. Patient education and experience</p> <p>Secondary 5.1 Proportion of patients with established or high risk for ASCVD who have a documented discussion with a member of the multidisciplinary team about their treatment goals, preference, and values at least annually.</p> <p>Numerator: Patients with established or high risk for ASCVD who have a documented discussion about their treatment goals, preference, and values with a member of the multidisciplinary team at least annually.</p> <p>Denominator: Patients with established or high risk for ASCVD.</p> <p>Secondary 5.2 Proportion of patients with established or high risk for ASCVD who have their satisfaction about risk factor control captured at least annually.</p> <p>Numerator: Patients with established or high risk for ASCVD who have their satisfaction about risk factor control captured at least annually.</p> <p>Denominator: Patients with established or high risk for ASCVD.</p>
<p>Domain 6. Outcomes</p> <p>Treatment outcomes</p> <p>Main 6.1 Proportion of patients with established or high risk for ASCVD who have LDL-C levels at or below that recommended for their estimated cardiovascular risk.</p>

Continued

Table 1 Continued

Numerator: Patients with established or high risk for ASCVD who have LDL-C levels at or below that recommended for their estimated cardiovascular risk. ^f
Denominator: Patients with established or high risk for ASCVD who have no contraindication, refusal, or history of intolerance to statins, ezetimibe and PCSK9 inhibitors.
Main 6.2 Proportion of patients with established ASCVD and diabetes who have HbA1c levels <7.0% (53 mmol/mol).
Numerator: Patients with established ASCVD and diabetes who have their HbA1c levels <7.0% (53 mmol/mol).
Denominator: Patients with established ASCVD and diabetes who have no contraindication, refusal, or history of intolerance to optimal glycaemic control.
Main 6.3 Proportion of patients with established or high risk for ASCVD who stop smoking.
Numerator: Patients with established or high risk for ASCVD who self-identify as non-smokers.
Denominator: Patients with established or high risk for ASCVD who previously self-identified as smokers.
Secondary 6.1 Proportion of patients with established ASCVD who have their BP well-controlled.
Numerator: Patients with established ASCVD and hypertension who achieve their target BP levels. ^g
Denominator: Patients with established ASCVD who have hypertension and no contraindication, refusal, or history of intolerance to optimal BP control.
Disease outcomes
Secondary 6.2 Annual rate of all-cause mortality.
Secondary 6.3 Annual rate of cardiovascular mortality.
Secondary 6.4 Annual rate of cardiovascular hospitalization.
Secondary 6.5 Annual rate of non-fatal myocardial infarction.
Treatment complications
Secondary 6.6 Annual rate of bleeding resulting in hospital admission.

^aScreening for hypertension involves office BP measurement, ambulatory BP monitor, and/or home-measurements using a validated device.

^bPeripheral artery disease is defined as carotid artery stenosis irrespective of clinical symptoms, carotid/lower extremity artery revascularization, or symptomatic lower extremity artery disease. Appropriate antiplatelet therapy is defined as aspirin 75–100 mg daily or Clopidogrel 75 mg daily in case of aspirin intolerance.

^cSupplementary material online, Appendix Table A4. Blood pressure lowering drugs, with absolute and relative contraindications.

^dAppropriate antiplatelet therapy for non-cardioembolic ischaemic (or embolic of undetermined source) stroke or TIA is defined as aspirin 75–100 mg daily or Clopidogrel 75 mg daily in case of aspirin intolerance.

^eAccording to the Academic Research Consortium criteria for high bleeding risk.

^fLDL-C targets for patients with established ASCVD is <1.4 mmol/L (55 mg/dL) and >50% reduction from baseline. LDL-C targets for patients with high risk for ASCVD is <1.8 mmol/L (70 mg/dL) and >50% reduction from baseline.

^gControlled BP is defined as home-measured/mean ambulatory BP between 120–129/70–80 mmHg for those <65 years of age, and between 130–139/70–80 mmHg for those ≥65 years of age.

ASCVD, atherosclerosis cardiovascular disease; BP, blood pressure; BMI, body mass index; CT, computed tomography; CVD, cardiovascular disease; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonists; HbA1c, glycated haemoglobin; LDL-C, low-density lipoprotein cholesterol; PCSK 9, proprotein convertase subtilisin/kexin type 9; SGLT2i, sodium/glucose cotransporter-2 inhibitors; TIA, transient ischaemic attack.

outcomes is less established compared with process QIs, they may provide a qualitative assessment of the allocations of resources which are needed for the delivery of optimal care.⁷ As such, three main and two secondary QIs were included in this domain. The main QIs capture the availability of a multidisciplinary team that is dedicated for the delivery of lifestyle modification advice and medication adherence counselling (**Main 1.1**), smoking cessation programmes (**Main 1.2**) and investigations including a 12-lead electrocardiogram, Holter monitoring, transthoracic echocardiography, and CT calcium scoring (**Main 1.3**) for patients with established or high risk for ASCVD, which are fundamental aspects of cardiovascular disease protection (**Table 1**).^{5,21,22}

The **Secondary 1.1** QI within the structural framework domain evaluates the healthcare centre's participation in a registry that allows the capture of data relevant to ASCVD given the vital role longitudinal databases have in monitoring patterns of ASCVD risk factors² and outcomes.³⁵ Moreover, disease self-monitoring for patients with diabetes and/or hypertension has a role in improving treatment adherence and control (**Secondary 1.2**) (**Table 1**).^{28,29}

Domain 2: Risk assessment

The estimation of risk is the cornerstone of ASCVD prevention because it determines the appropriateness of the preventive

interventions needed.⁵ For patients with established ASCVD, the annual measurement of kidney function (**Main 2.1**)^{36,37} and lipid profile (**Main 2.2**),²⁷ as well as the screening for diabetes (**Main 2.3**),²⁸ and hypertension (**Main 2.4**)²⁹ can help identify those with suboptimal risk factor modification and requiring treatment optimization.³⁸ Furthermore, glycaemic control in patients with diabetes mellitus who have no history of established ASCVD has prognostic implications on the development of cardiovascular complications, and thus regular monitoring to glycated haemoglobin (HbA1c) in this group of patients may be used as an indicator of care quality (**Main 2.5**).²⁸ The provision of systems that allow the follow up of patients with established and those with high risk for ASCVD facilitates the implementation of these monitoring/screening measures, but may not be feasible in all healthcare systems (**Secondary 2.1**) (**Table 1**).

Domain 3: Care for people at risk for ASCVD

A number of primary preventive measures have a role in delaying the onset of cardiovascular events and in improving clinical outcomes in individuals at high or very high risk for ASCVD.⁵ For patients between 40 and 70 years of age at a very high risk for the development of ASCVD (e.g. with diabetes) who have low-density lipoprotein cholesterol levels ≥ 1.8 mmol/L (≥70 mg/dL), lipid lowering therapy has shown to be effective in reducing major vascular events (**Main**

3.1).^{27,39} In addition, the prescription of renin-angiotensin-aldosterone system inhibitors for patients with diabetes who have a concomitant chronic kidney disease and/or hypertension has been shown to improve cardiovascular outcomes (**Main 3.2**).^{28,29} Furthermore, sodium–glucose cotransporter 2 (SGLT2) inhibitors have recently emerged as cardioprotective agents for patient with diabetes who have chronic kidney disease (**Secondary 3.1**) (*Table 1*).^{28,40,41}

Domain 4: Care for patients with established ASCVD

For patients with established ASCVD, intensive measures are needed to prevent further cardiovascular events.⁵ Whilst these measures are initially based on lifestyle modification such as smoking cessation, pharmacotherapies play a role in slowing and/or delaying disease progression and preventing unfavourable outcomes. As such, the QIs within this domain focus on medical interventions for patients with established ASCVD. That is the prescription of: (i) SGLT2 inhibitors or glucagon-like peptide-1 receptor agonist for patients with diabetes (**Main 4.1**),²¹ (ii) appropriate antiplatelet therapy for patients with symptomatic peripheral artery disease (**Main 4.2**),³⁰ (iii) blood pressure lowering treatment for patients with readings $\geq 140/90$ mmHg (**Main 4.3**),²⁹ (iv) appropriate antiplatelet therapy following a non-cardioembolic ischaemic (or embolic of undetermined source) stroke (**Secondary 4.1**),⁴² and (v) proton pump inhibitors for those on antiplatelet therapy and who have high risk for gastrointestinal bleeding (**Secondary 4.2**).⁴³ Furthermore, cardiac rehabilitation has an important role in secondary prevention following an acute cardiovascular event and elective coronary revascularization (**Main 4.4**) (*Table 1*).¹²

Domain 5: Patient education and experience

Shared decision-making about treatment benefit, risk modifiers, and lifestyle changes in accordance to patient preferences is an essential element of ASCVD prevention.⁵ Thus, recording the delivery of patient education for those with established or high risk for ASCVD about their treatment goals, preference is a QI (**Secondary 5.1**). In addition, the assessment of patient satisfaction with care quality is also an indicator of care quality (**Secondary 5.2**) (*Table 1*).

Domain 6: Outcomes

The collection of outcome measures pertinent to ASCVD or its treatment provides information about the effectiveness and the safety of management strategy. For patients with established ASCVD, achieving the target levels of low-density lipoprotein cholesterol (**Main 6.1**),²⁷ the target level of HbA1c in the presence of diabetes (**Main 6.2**),⁴⁴ the cessation of smoking (**Main 6.3**),⁵ and controlling blood pressure (**Secondary 6.1**)²⁹ have a role in determining the success of treatment and in improving clinical outcomes (*Table 1*). Achieving blood pressure control has been proposed as a secondary QI given concerns from the Working Group members on the feasibility of the measurement of this QI which carries the same level of clinical relevance as the other main QIs within this domain.

Furthermore, recording annual rates of all-cause mortality (**Secondary 6.2**), cardiovascular mortality (**Secondary 6.3**), cardiovascular hospitalization (**Secondary 6.4**), non-fatal myocardial infarction (**Secondary 6.5**), and hospitalized major bleeding events

(**Secondary 6.6**) provides information about the outcomes of care (*Table 1*). However, adjustments for baseline risk and other patient characteristics may be needed when interpreting the results of such outcome QIs.⁴⁵ Furthermore, whilst the measurement duration for these QIs is 12 months, longer follow-up may be needed to capture sufficient events, especially in lower-risk population.

Discussion

By way of a joint working group between the EAPC, members of the Task Force of the 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice and the ESC Patient Forum, 17 main and 14 secondary QIs for ASCVD prevention have been developed across 6 key domains of care. This work has been conducted under the auspice of the ESC Quality Indicator Committee using the ESC standardized methodology of QI development.⁷ The QIs presented in this document align with recommendations of the 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice and do not overlap or conflict with published ESC QIs.^{32–34} It is hoped that by developing such QIs and providing the specifications needed for their implementation, local, regional, national, or international initiatives aiming to improve the quality of ASCVD prevention can be created in accordance to the specific needs of individual centres or countries.

Monitoring and reporting the structure, process, and/or outcome of care has become a requirement for modern healthcare systems.⁴⁶ QIs provide a means by which this may be undertaken and performance evidenced.⁴⁷ QIs also help evaluate the effectiveness of quality improvement initiatives and may be used to ascertain if patient's perceptions of their care have been considered.⁷ Additionally, QIs can be used as an advocacy tool to demonstrate to health politicians the gaps of ASCVD prevention in different regions or countries. Although the literature describes a range of quality measures for ASCVD,^{8,12–19} until now there has been no set of QIs that span the breadth of cardiovascular prevention. We believe this document describes a QI set that covers the key domains of ASCVD prevention care.

We believe that our approach to the development of the ESC QIs for cardiovascular disease prevention will facilitate their implementation in clinical practice. First, the achievement of a systematic review of the literature ensured that the developed QIs are derived from, and supported by, evidence. Second, the inclusiveness of our Working Group provided far-reaching representation through the close working with patients, Task Force members of the 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice, and EAPC experts who have a track records in the field of preventive cardiology.^{14,31} As such, our work integrates, and complements, current ESC and EAPC activities that aim to improve the quality of ASCVD prevention care across Europe. Third, the methodological approach used to develop these QIs enhances their incorporation into international registries that aim to capture key aspects of care delivery across a number of cardiovascular disease conditions, such as the ESC European Unified Registries On Heart Care Evaluation and Randomized Trials (EuroHeart) project.⁴⁸

While our work has a number of strengths, it does, however, have several evident limitations. First, we acknowledge that it may be

difficult for a healthcare centre to adopt all the QIs given that fact that they cover many aspects of care, which may be delivered in different settings. Therefore, the Working Group opted not to design a composite QI because such an indicator could disadvantage centres that rely on community or smaller hospital services. Also, the Working Group believes that efforts should be made to ensure that performance is measured along the continuum of patient care pathway. This may be achieved through the integration of systems used across various clinical settings, such as electronic healthcare records, clinical registries and quality improvement projects.⁴⁷ Evaluating the quality of care based on data that do not span the full breadth of cardiovascular prevention may result in unintended consequences and system 'gaming' to improve the scores rather than the actual care quality.⁷ Second, the methodology used for the development relied on expert opinion. One may argue that this approach created subjectivity in the selection process. However, the use of the modified Delphi method, the involvement of patient representatives, and the application of the ESC criteria to guide the voting provided a level of standardization to the process. Third, the developed QIs will require continuous update and revision as new evidence arises, and feasibility data become available.

Conclusion

This document defines the 2021 ESC QIs for Cardiovascular Disease prevention, which have been co-developed by the members of the Task Force of the 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice, the ESC Patient Forum, the Quality Indicator Committee, and EAPC. In total, 17 main and 14 secondary QIs have been defined across six key domains of ASCVD preventive care. These indicators cover the breadth of ASCVD prevention care, including: (i) structural framework, (ii) risk assessment, (iii) care for people at risk for ASCVD, (iv) care for patients with established ASCVD, (v) patient education and experience, and (vi) outcomes. Their implementation in clinical practice will standardize the evaluation of cardiovascular preventive care.

Supplementary material

Supplementary material is available at *European Journal of Preventive Cardiology* online.

Funding

S.A. is funded by the European Society of Cardiology.

Data Availability Statement

The data underlying this article are available in the article and in its online supplementary material.

Conflict of interest: CPG: Consultancy (AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer-Ingelheim, Chiesi, Daiichi Sankyo, Menarini). Speaker fees (AstraZeneca, Menarin, Raisio Group, Wondr Medical, Zydus). Editorship (Deputy Editor: *European Heart Journal Quality of Care and Clinical Outcomes*, Oxford University Press). Grants (British Heart Foundation, National Institute for Health Research, Horizon 2020,

Abbott Diabetes, Bristol Myers Squibb). Advisory Board (Amgen, Bayer, Bristol Myers Squibb, Boehringer-Ingelheim, Chiesi, Daiichi Sankyo, Menarini). Leadership (NICE Indicator Advisory Committee, Chair ESC Quality Indicator Committee).

References

1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020;**396**:1204–1222.
2. Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in U.S. adults, 1999–2018. *N Engl J Med* 2021;**384**:2219–2228.
3. Kotseva K, Wood D, De Bacquer D. Determinants of participation and risk factor control according to attendance in cardiac rehabilitation programmes in coronary patients in Europe: EUROASPIRE IV survey. *Eur J Prev Cardiol* 2018;**25**:1242–1251.
4. Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos EA, Maggioni AP, Kazakiewicz D, May HT, De Smedt D, Flather M, Zuhke L, Beltrame JF, Huculeci R, Tavazzi L, Hindricks G, Bax J, Casadei B, Achenbach S, Wright L, Vardas P; European Society of Cardiology. European Society of Cardiology: cardiovascular disease statistics 2019. *Eur Heart J* 2020;**41**:12–85.
5. Vissers FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglul L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). *Eur Heart J* 2021;**42**:3227–3337.
6. De Smedt D, De Backer T, Petrovic M, De Backer G, Wood D, Kotseva K, De Bacquer D. Chronic medication intake in patients with stable coronary heart disease across Europe: evidence from the daily clinical practice. Results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes (EUROASPIRE IV) Registry. *Int J Cardiol* 2020;**300**:7–13.
7. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, Ludman P, Maggioni A, Price S, Weston C, Casadei B, Gale CP. European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. *Eur Heart J Qual Care Clin Outcomes* 2020; qcaa069. doi: 10.1093/ehjqcco/qcaa069.
8. Department of Health and Human Services Agency for Healthcare Research and Quality, Guide to Prevention Quality Indicators: Hospital Admission for Ambulatory Care Sensitive Conditions. 2002. <https://www.ahrq.gov/downloads/pub/ahrqqi/pqiguide.pdf> (09 June 2021).
9. Ramalho A, Lobo M, Duarte L, Souza J, Santos P, Freitas A. Landscapes on prevention quality indicators: a spatial analysis of diabetes preventable hospitalizations in Portugal (2016–2017). *Int J Environ Res Public Health* 2020;**17**:8387.
10. Ramalho A, Castro P, Lobo M, Souza J, Santos P, Freitas A. Integrated quality assessment for diabetes care in Portuguese primary health care using prevention quality indicators. *Prim Care Diabetes* 2021;**15**:507–512.
11. Spertus JA, Bonow RO, Chan P, Diamond GA, Drozda JP, Kaul S, Krumholz HM, Masoudi FA, Normand S-LT, Peterson ED, Radford MJ, Rumsfeld JS; ACCF/AHA Task Force on Performance Measures. ACCF/AHA new insights into the methodology of performance measurement. *Circulation* 2010;**122**:2091–2106.
12. Ambrosetti M, Abreu A, Corrà U, Davos CH, Hansen D, Frederix I, Iliou MC, Pedretti RF, Schmid JP, Vigorito C, Voller H, Wilhelm M, Piepoli MF, Bjarnason-Wehrens B, Berger T, Cohen-Solal A, Cornelissen V, Dendale P, Doehner W, Gaita D, Gevaert AB, Kemps H, Kraenkel N, Laukkanen J, Mendes M, Niebauer J, Simonenko M, Zwisler AO. Secondary prevention through comprehensive cardiovascular rehabilitation: from knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. *Eur J Prev Cardiol* 2020;doi: 10.1177/2047487320913379.
13. Campbell SM, Ludt S, Lieshout JV, Boffin N, Wensing M, Petek D, Grol R, Roland MO. Quality indicators for the prevention and management of cardiovascular disease in primary care in nine European countries. *Eur J Cardiovasc Prev Rehabil* 2008;**15**:509–515.
14. Abreu A, Frederix I, Dendale P, Janssen A, Doherty P, Piepoli MF, Völler H, Davos CH; Secondary Prevention and Rehabilitation Section of EAPC. Standardization and quality improvement of secondary prevention through cardiovascular rehabilitation programmes in Europe: the avenue towards EAPC

- accreditation programme: A position statement of the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology (EAPC). *Eur J Prev Cardiol* 2020;doi:https://doi.org/10.1177/2047487320924912.
15. Casey DE Jr, Thomas RJ, Bhalla V, Commodore-Mensah Y, Heidenreich PA, Kolte D, Muntner P, Smith SC Jr, Spertus JA, Windle JR, Wozniak GD, Ziaeiian B. 2019 AHA/ACC clinical performance and quality measures for adults with high blood pressure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. *Circ Cardiovasc Qual Outcomes* 2019;**12**:e000057.
 16. Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC Jr, Havas S, Labarthe DR, Limacher MC, Lloyd-Jones DM, Mora S, Pearson TA, Radford MJ, Smetana GW, Spertus JA, Swegler EW; Preventive Cardiovascular Nurses Association. AHA/ACC [corrected] 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease): developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. *Circulation* 2009;**120**: 1296–1336.
 17. Drozda JP Jr, Ferguson TB Jr, Jneid H, Krumholz HM, Nallamothu BK, Olin JW, Ting HH. 2015 ACC/AHA focused update of secondary prevention lipid performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. *J Am Coll Cardiol* 2016;**67**:558–587.
 18. Thomas RJ, Balady G, Banka G, Beckie TM, Chiu J, Gokak S, Ho PM, Keteyian SJ, King M, Lui K, Pack Q, Sanderson BK, Wang TY. 2018 ACC/AHA clinical performance and quality measures for cardiac rehabilitation: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. *Circ Cardiovasc Qual Outcomes* 2018;**11**:e000037.
 19. Burge FI, Bower K, Putnam WW, Cox JL. Quality indicators for cardiovascular primary care. *Can J Cardiol* 2007;**23**:383–388.
 20. Grace SL, Poirier P, Norris CM, Oakes GH, Somanader DS, Suskin N. Pan-Canadian development of cardiac rehabilitation and secondary prevention quality indicators. *Can J Cardiol* 2014;**30**:945–948.
 21. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumgartner H, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibellund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2021;ehab368.
 22. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, Barrabás JA, Boriani G, Braunschweig F, Brignole M, Burri H, Coats AJS, Deharo J-C, Delgado V, Diller G-P, Israel CW, Keren A, Knops RE, Kotecha D, Leclercq C, Merkely B, Starck C, Thylén I, Tolosana JM; ESC Scientific Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA). *Eur Heart J* 2021;**42**: 3427–3520.
 23. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;**372**:n71.
 24. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney M-T, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen M-L, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binnos S; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J* 2016;**37**:2315–2381.
 25. Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, Francis GA, Genest J, Grégoire J, Grover SA, Gupta M, Hegele RA, Lau D, Leiter LA, Leung AA, Lonn E, Mancini GBJ, Manjoo P, McPherson R, Ngu D, Piché M-E, Poirier P, Sievenpiper J, Stone J, Ward R, Wray W. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. *Can J Cardiol* 2021;**37**: 1129–1150.
 26. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Virani SS, Williams KA, Yeboah J, Ziaeiian B. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019;**140**:e596–e646.
 27. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M-R, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). *Eur Heart J* 2020;**41**:111–188.
 28. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). *Eur Heart J* 2020;**41**: 255–323.
 29. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *Eur Heart J* 2018;**39**:3021–3104.
 30. Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T, Collet J-P, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Röther J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J* 2018;**39**:763–816.
 31. Wilhelm M, Abreu A, Adami PE, Ambrosetti M, Antonopoulou M, Biffi A, Cavarretta E, D'Ascenzi F, Gibson I, Grobbee DE, Iliou M-C, Koskinas K, Marques-Vidal P, Nixdorff U, Papadakis M, Piepoli MF, Vassiliou V, Wood D, Dendale P, Halle M. EAPC core curriculum for preventive cardiology. *Eur J Prev Cardiol* 2021;zwab017.
 32. Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet J-P, Fox KAA, Gale CP, Huber K, Iakobishvili Z, Keys A, Lambrinou E, Leonardi S, Lettino M, Masouidi FA, Price S, Quinn T, Swahn E, Thiele H, Timmis A, Tubaro M, Vrints CJM, Walker D, Bueno H, Halvorsen S, Jernberg T, Jortveit J, Blöndal M, Ibanez B, Hassager C. 2020 update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group. *Eur Heart J Acute Cardiovasc Care* 2021;**10**:224–233.
 33. Arbelo E, Aktaa S, Bollmann A, D'Avila A, Drossart I, Dwight J, Hills MT, Hindricks G, Kusumoto FM, Lane DA, Lau DH, Lettino M, Lip GYH, Lobban T, Pak HN, Potpara T, Saenz LC, Van Gelder IC, Varosy P, Gale CP, Dagres N. Quality indicators for the care and outcomes of adults with atrial fibrillation. *Europace* 2021;**23**:494–495.
 34. Aktaa S, Abdin A, Arbelo E, Burri H, Vernooy K, Blomström-Lundqvist C, Boriani G, Defaye P, Deharo JC, Drossart I, Foldager D, Gold MR, Johansen JB, Leyva F, Linde C, Michowitz Y, Kronborg MB, Slotwinger D, Steen T, Tolosana JM, Tzeis S, Varma N, Glikson M, Nielsen JC, Gale CP. European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. *Europace* 2021;euab193.
 35. Figtree GA, Vernon ST, Hadziosmanovic N, Sundström J, Alfredsson J, Arnott C, Delatour V, Leósdóttir M, Hagström E. Mortality in STEMI patients without

- standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. *The Lancet* 2021;**397**:1085–1094.
36. Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, Gutierrez OM, Hosseinpanah F, Iseki K, Kenealy T, Klein B, Kronenberg F, Lee BJ, Li Y, Miura K, Navaneethan SD, Roderick PJ, Valdivielso JM, Visseren FLJ, Zhang L, Gansevoort RT, Hallan SI, Levey AS, Matsushita K, Shalev V, Woodward M. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. *BMJ* 2019;**364**:k5301.
 37. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2020;**395**:709–733.
 38. Si S, Moss JR, Sullivan TR, Newton SS, Stocks NP. Effectiveness of general practice-based health checks: a systematic review and meta-analysis. *Br J Gen Pract* 2014;**64**:e47–e53.
 39. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet* 2008;**371**:117–125.
 40. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med* 2017;**377**:644–657.
 41. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015;**373**:2117–2128.
 42. Chiarito M, Sanz-Sánchez J, Cannata F, Cao D, Sturla M, Panico C, Godino C, Regazzoli D, Reimers B, De Caterina R, Condorelli G, Ferrante G, Stefanini GG. Monotherapy with a P2Y₁₂ inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. *Lancet* 2020;**395**:1487–1495.
 43. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). *Eur Heart J* 2020;**41**:407–477.
 44. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu P-L, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 2019;**380**:2295–2306.
 45. National Quality Forum. Risk adjustment for sociodemographic factors. https://www.qualityforum.org/Publications/2014/08/Risk_Adjustment_for_Socioeconomic_Status_or_Other_Sociodemographic_Factors.aspx (20 April 2021).
 46. National Library of Quality Indicators. National Institute for Health and Care Excellence. <https://www.nice.org.uk/standards-and-indicators/index/AII/AII/7> (15 December 2020).
 47. Bhatt DL, Drozda JP, Shahian DM, Chan PS, Fonarow GC, Heidenreich PA, Jacobs JP, Masoudi FA, Peterson ED, Welke KF. ACC/AHA/STS statement on the future of registries and the performance measurement enterprise. *J Am Coll Cardiol* 2015;**66**:2230–2245.
 48. Batra G, Aktaa S, Wallentin L, Maggioni AP, Wilkinson C, Casadei B, Gale CP. Methodology for the development of international clinical data standards for common cardiovascular conditions: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). *Eur Heart J Qual Care Clin Outcomes* 2021;qcab052.low-density lipoprotein cholesterol